CBIC CIC - CBIC Certified Infection Control Exam

The CBIC Certified Infection Control Exam Study Guide (6th edition) identifies clindamycin as one of the antimicrobials most strongly associated with an increased risk of Clostridioides difficile infection (CDI). Clindamycin has a profound impact on the normal intestinal microbiota, significantly disrupting protective gut flora that ordinarily suppress C. difficile overgrowth. This disruption creates an environment conducive to colonization and toxin production by C. difficile, leading to clinical infection.

Historically, clindamycin was one of the first antibiotics clearly linked to large outbreaks of CDI, and it remains a high-risk agent today. The Study Guide notes that antibiotics with broad anaerobic coverage—including clindamycin, fluoroquinolones, third-generation cephalosporins, and carbapenems—are particularly associated with CDI because they extensively alter gastrointestinal microbial balance.

The other options listed carry comparatively lower risk. Amoxicillin has a modest association but is not among the highest-risk agents. Aztreonam has limited anaerobic activity and is less disruptive to gut flora. Tobramycin, an aminoglycoside, has minimal impact on intestinal microbiota when administered parenterally and is not commonly associated with CDI.

Recognizing high-risk antimicrobials is essential for antimicrobial stewardship, CDI prevention strategies, and CIC® exam success. Clindamycin is classically tested and should be readily identified as a major CDI risk factor.

Measures of central tendency (mean, median, mode) and dispersion (standard deviation) are statistical tools used to summarize data, such as the duration of surgical procedures, which can help infection preventionists identify trends or risks for surgical site infections. The Certification Board of Infection Control and Epidemiology (CBIC) supports the use of data analysis in the "Surveillance and Epidemiologic Investigation" domain, aligning with epidemiological principles outlined by the Centers for Disease Control and Prevention (CDC). The question provides a data set of 2, 2, 3, 4, and 9, and requires determining the correct statement by calculating these measures.

Mean: The mean is the average of the data set, calculated by summing all values and dividing by the number of observations. For the data set 2, 2, 3, 4, and 9:(2 + 2 + 3 + 4 + 9) ÷ 5 = 20 ÷ 5 = 4. Thus, the mean is 4, making Option C correct.

Median: The median is the middle value when the data set is ordered. With five values (2, 2, 3, 4, 9), the middle value is the third number, which is 3. Option A states the median is 2, which is incorrect.

Mode: The mode is the most frequently occurring value. In this data set, 2 appears twice, while 3, 4, and 9 appear once each, making 2 the mode. Option B states the mode is 3, which is incorrect.

Standard Deviation: The standard deviation measures the spread of data around the mean. For a small data set like this, the calculation involves finding the variance (average of squared differences from the mean) and taking the square root. The mean is 4, so the deviations are: (2-4)² = 4, (2-4)² = 4, (3-4)² = 1, (4-4)² = 0, (9-4)² = 25. The sum of squared deviations is 4 + 4 + 1 + 0 + 25 = 34. The variance is 34 ÷ 5 = 6.8, and the standard deviation is √6.8 ≈ 2.61 (not 7). Option D states the standard deviation is 7, which is incorrect without further context (e.g., a population standard deviation with n-1 denominator would be √34 ≈ 5.83, still not 7).

The CBIC Practice Analysis (2022) and CDC guidelines encourage accurate statistical analysis to inform infection control decisions, such as assessing surgical duration as a risk factor for infections. Based on the calculations, the mean of 4 is the only correct statement among the options, confirming Option C as the answer. Note that the standard deviation of 7 might reflect a miscalculation or misinterpretation (e.g., using a different formula or data set), but with the given data, it does not hold.

The Certification Study Guide (6th edition) identifies coagulase-negative staphylococci (CoNS) as among the most common causes of surgical site infections following orthopedic implant procedures, including total hip replacement. These organisms are part of normal human skin flora and are therefore a frequent source of contamination during surgery, even when aseptic technique is followed. Their importance is heightened in procedures involving prosthetic material because CoNS have a strong ability to adhere to foreign bodies and form biofilms, which protect bacteria from host defenses and antimicrobial therapy.

The study guide emphasizes that SSIs following joint replacement procedures often present within 30 to 60 days postoperatively and are typically caused by gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci. CoNS are especially associated with indolent or delayed infections involving implanted devices, making them a critical teaching point in joint replacement programs.

The other organisms listed are less likely causes in this setting. Escherichia coli and Pseudomonas aeruginosa are more commonly associated with gastrointestinal, urinary, or moist environmental sources rather than clean orthopedic procedures. Group A streptococci may cause acute SSIs but are far less common in prosthetic joint infections.

Understanding organism-specific risks allows infection preventionists to target prevention strategies, antimicrobial prophylaxis, and surveillance effectively—key competencies tested on the CIC exam.

Multi-drug resistant (MDR) Klebsiella pneumoniae in a high-risk area like the ICU requires urgent investigation because:

It spreads rapidly via contaminated hands or equipment.

It poses a serious risk to immunocompromised patients.

An outbreak could lead to severe hospital-acquired infections (HAIs).

Why the Other Options Are Incorrect?

A. One blood isolate of Streptococcus agalactiae in the nursery – Single cases are not indicative of an outbreak.

B. Two isolates of Staphylococcus aureus in postoperative surgical sites – Common post-surgical pathogen; requires monitoring but not immediate outbreak investigation.

D. Two blood isolates of coagulase-negative staphylococci in the oncology unit – Common contaminants in blood cultures and not immediately alarming.

CBIC Infection Control Reference

APIC guidelines prioritize investigating MDR pathogens in high-risk units, such as ICU, to prevent transmission​.

When implementing a multimodal strategy (or bundle) for hand hygiene, the infection preventionist should first assess barriers to compliance before implementing solutions.

Step-by-Step Justification:

Understanding Barriers First:

Identifying barriers (e.g., lack of access to sinks, high workload, or poor compliance culture) is critical for effective intervention​.

APIC Guidelines on Hand Hygiene Improvement:

Strategies must be tailored based on the institution's specific challenges​.

Why Other Options Are Incorrect:

A. Signage for hand hygiene reminders:

Signage alone is insufficient without addressing systemic barriers.

B. Cost-effectiveness of hand hygiene products:

While important, cost analysis comes after identifying compliance barriers.

C. Availability of gloves in the patient care area:

Gloves do not replace hand hygiene and may lead to lower compliance.

CBIC Infection Control References:

APIC/JCR Workbook, "Hand Hygiene Compliance and Institutional Barriers"​.

APIC Text, "Hand Hygiene Improvement Strategies"​.

The Certification Study Guide (6th edition) explains that assessment of Mycobacterium tuberculosis (MTB) risk in healthcare settings begins with evaluating the likelihood that patients with active TB will present to the facility. One of the most important determinants of this likelihood is the incidence of active TB disease in the community served by the healthcare facility. Facilities serving populations with higher TB prevalence are at increased risk of exposure events and must tailor their TB prevention and control programs accordingly.

The study guide emphasizes that TB risk assessments are population-based and epidemiologic in nature. Community TB rates directly influence the frequency with which undiagnosed or unsuspected infectious TB patients may enter the healthcare system, potentially exposing healthcare personnel (HCP) and other patients. This factor drives decisions regarding surveillance intensity, education, respiratory protection programs, and engineering controls.

The other options represent control measures or outcomes, not primary risk determinants. The number of airborne infection isolation rooms reflects facility preparedness, not exposure risk. Rates of positive HCP screening tests may indicate past exposure but are not used to assess initial risk. Compliance with N-95 fit testing is a program performance indicator, not a measure of TB exposure likelihood.

CIC exam questions commonly distinguish between risk assessment inputs versus mitigation strategies. Recognizing community TB incidence as the foundational risk factor is essential for accurate TB program planning and compliance with recommended infection prevention standards.

A process measure assesses how well healthcare personnel follow specific procedures known to prevent infection. In the case of CAUTI (Catheter-Associated Urinary Tract Infection), monitoring staff compliance with proper insertion technique is a direct process measure.

According to the APIC/JCR Workbook, effective CAUTI prevention involves evaluating compliance with proper catheter insertion and maintenance practices. Monitoring this behavior is a process measure that directly affects outcomes like infection rate reduction.

The CBIC Study Guide also emphasizes using compliance with evidence-based insertion techniques as a strategy to measure and improve CAUTI prevention efforts.

APIC Text notes that “a process measure focuses on a process or the steps in a process that leads to a specific outcome.” This includes monitoring healthcare staff performance related to proper catheter insertion and care.

Incorrect answer rationale:

A. CAUTI rate per 1000 catheter days – This is an outcome measure, not a process measure.

B. Standardized Infection Ratio per unit – Also an outcome/benchmarking metric.

C. Rate of bloodstream infections secondary to CAUTI – This is an outcome, not a process.

Empiric antibiotic therapy is the immediate initiation of antibiotics based on clinical judgment before laboratory confirmation of an infection. In this case, the presence of fever, erythema, and tenderness at the central line site suggests a possible bloodstream infection, prompting empiric treatment with vancomycin.

Step-by-Step Justification:

Initiation Before Lab Confirmation:

Empiric therapy starts treatment based on symptoms while awaiting culture results​.

Prevents Complications:

Delayed treatment in central line-associated bloodstream infections (CLABSI) can lead to sepsis.

Common in High-Risk Situations:

Empiric treatment is used in cases where waiting for lab results could worsen the patient’s condition.

Why Other Options Are Incorrect:

B. Prophylactic:

Prophylactic antibiotics are given to prevent infection, not to treat an existing one.

C. Experimental:

Experimental treatment refers to clinical trials or unproven therapies, which does not apply here.

D. Broad spectrum:

Broad-spectrum antibiotics cover multiple bacteria, but empiric therapy may be narrow-spectrum based on suspected pathogens​.

CBIC Infection Control References:

APIC Text, Chapter on Antimicrobial Stewardship and Empiric Therapy​.

The correct answer is D, "A device used one time on a patient during a procedure and then discarded," as this accurately describes a single-use medical device. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, a single-use device (SUD), also known as a disposable device, is labeled by the manufacturer for one-time use on a patient and is intended to be discarded afterward to prevent cross-contamination and ensure patient safety. This definition is consistent with regulations from the Food and Drug Administration (FDA), which designate SUDs as devices that should not be reprocessed or reused due to risks of infection, material degradation, or failure to restore sterility (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). Examples include certain syringes, catheters, and gloves, which are designed for single use to eliminate the risk of healthcare-associated infections (HAIs).

Option A (a device which can be used on a single patient) is too vague and could apply to both single-use and reusable devices, as reusable devices are also often used on a single patient per procedure before reprocessing. Option B (a device that is sterilized and can be used again on the same patient) describes a reusable device, not a single-use device, as sterilization and reuse are not permitted for SUDs. Option C (a device used on a patient and reprocessed prior to being used again) refers to a reusable device that undergoes reprocessing (e.g., sterilization), which is explicitly prohibited for SUDs under manufacturer and regulatory guidelines.

The focus on discarding after one use aligns with CBIC’s emphasis on preventing infection through adherence to device labeling and safe reprocessing practices, ensuring that healthcare facilities avoid the risks associated with improper reuse of SUDs (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This practice is critical to maintaining a sterile and safe healthcare environment.